目的：探讨齐拉西酮、奥氮平在初诊精神分裂症患者中的疗效比较及其对糖脂代谢的影响。方法选取2012年9月~2014年6月我院收治的精神分裂症初诊患者共有97例，随机分为观察组(n=49)和对照组(n=48)。观察组予齐拉西酮治疗，对照组予奥氮平治疗，比较两组的治疗疗效、对糖脂代谢的影响及不良反应。结果观察组给予齐拉西酮治疗的总有效率为87.8%，与对照组给予奥氮平治疗的87.5%相比，差异无统计学意义(χ2=0.114，P=0.735)。治疗后，观察组的FBS、INS、HDL、LDL、TG、TC和IRI指标均显著低于对照组(t=5.715，P=0.000；t=10.969，P=0.000；t=2.276，P=0.025；t=7.756，P=0.000；t=2.713，P=0.008；t=3.906，P=0.000；t=11.814，P=0.000)。观察组、对照组嗜睡、口渴、肝功能异常、心动过速和坐立不安不良反应比较，差异无统计学意义(χ2=0.351，P=0.554；χ2=0.001，P=0.977；χ2=0.292，P=0.589；χ2=0.429，P=0.513；χ2=0.056，P=0.812)。结论齐拉西酮、奥氮平在初诊精神分裂症患者的治疗疗效和不良反应均相似，但齐拉西酮对糖脂代谢的影响更小，为治疗精神分裂症患者的首选。%Objective To investigate effect of ziprasidone and olanzapine in treatment of newly diagnosed schizophrenia patients and its effects on metabolism of glucose and lipid. Methods A total of 97 newly diagnosed schizophrenia pa-tients from September 2012 to June 2014 in our hospital were selected, and were randomly divided into observation group(n=49) and control group (n=48). The observation group was given ziprasidone treatment, while the control group was given olanzapine treatment. Effects of two groups were compared. Results The total effective rate of observa-tion group was 87.8%,while the total effective rate of control group was 87.5%,and there was no significant difference between two groups (χ2=0.114,P=0.735). After treatment, FBS, INS, HDL, LDL, TG, TC and IRI level of observation group were lower than that of control group(t=5.715,P=0.000;t=10.969,P=0.000;t=2.276,P=0.025;t=7.756,P=0.000;t=2.713,P=0.008; t=3.906,P=0.000; t=11.814,P=0.000). The sleepiness cases,thirsty cases,abnormal liver function cases,heartbeat tachycardia cases and tenterhooks cases of two groups had no significant difference(χ2=0.351,P=0.554;χ2=0.001,P=0.977; χ2=0.292,P=0.589; χ2=0.429,P=0.513; χ2=0.056,P=0.812). Conclusion Effect and adverse reac-tions of ziprasidone and olanzapine in the treatment of newly diagnosed schizophrenia patients are similar, but the ef-fect of ziprasidone on glucose and lipid metabolism is smaller.
展开▼
